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Soon after its discovery, endothelin-1 (ET-1) was identified as a key factor in controlling kidney function and promoting renal disease progression [1] , due to its vasoconstrictive action and mitogenic property. More recently, the role of ET-1 in fostering renal injury in chronic RVD was put forward, with a particular focus on the roles of ET receptors, ET-1 type A (ET A ) and ET-1 type B (ET B ) [2, 3] . Results from these studies documented the disparate effects of the selective antagonism of ET A receptor compared to dual ET A /ET B [3] or ET B receptor [2] blockade in a porcine model of chronic RVD. While ET A receptor antagonist improved hypertension, microvascular rarefaction and renal injury, dual ET A /ET B blunted the therapeutic effects, and single ET B receptor inhibition was ineffective.
In the current issue of the American Journal of Nephrology , Harvey et al. further investigated the involve- significantly improved podocyte survival, preserved VEGF production and attenuated apoptotic factor expression, promoting instead a pro-survival expression profile with the upregulation of p-akt and Bcl-2. These effects were not observed after ET B blockade, which conversely was harmful to hypoxic podocytes by inducing an increased s-Flt 1 secretion in the cell medium.
The first finding of this study is the beneficial effect of ET A -not shared by ET B -receptor antagonist on hypoxic podocytes. Although it is well known that ET-1 favours renal disease progression via the detrimental action of the peptide on podocytes, it is still a matter of debate whether selective ET A receptor over ET A /ET B receptor blockade should be preferred for the treatment of kidney diseases. In an aging-associated glomerulosclerosis model, the ET A selective antagonism was more effective than non-selective ET A /ET B receptor blockade in reversing glomerulosclerosis and attenuating podocyte structural damage [6] . Moreover, selective ET A receptor and nonselective ET A /ET B receptor blockades reduced both albuminuria and glomerular permeability in a model of diabetic nephropathy, but only selective ET A receptor blockade restored nephrin and podocin expression and decreased glomerular inflammation [7] . By contrast, results from transgenic mice indicated that podocyte-specific deletion of both ET A and ET B receptors was protective in diabetic mice, offering the rationale for hypothesizing that dual ET A /ET B is more beneficial than single ET A antagonism [8] . In such a controversial context, the new findings by Harvey et al. add support to the use of selective over non-selective ET-1 receptor blockade for the treatment of chronic RVD.
The second significant finding of this study relates to the mechanism underlying the ET A antagonist-mediated podocyte protection. Taking advantage of the use of VEGF neutralizing antibodies, Harvey et al. identified VEGF as a pivotal factor for podocyte protection mediated by the ET A receptor blockade, and proposed VEGF's scarce bioavailability as a potential explanation for the detrimental effects of single ET B receptor inhibition [4] . Podocytes are both the source and target of glomerular VEGF, which is essential for maintaining the normal podocyte function and phenotype. Among these, an elegant study by Eremina et al. [9] clearly demonstrated the protective role of podocyte-produced VEGF in the pathogenesis of renal thrombotic microangiopathy, indicating the importance of preserving podocyte VEGF production for maintaining glomerular filtration barrier health and function. The ability of ET A antagonist to affect VEGF production was previously described in animal models of diabetes, but was confined only to the heart. In type I diabetes, the administration of ET A antagonist normalized the downregulated levels of VEGF, and this paralleled the recovery of cardiac contraction [10] , while in a model of type II diabetes, a significant induction of myocardial VEGF expression was obtained after ET A antagonism treatment, and was associated with the restoration of the heart's capillary network [11] . Harvey et al. have now provided the first piece of evidence that ET A antagonism can have a direct effect on glomerular podocytes through VEGF.
The in vitro approach of this study would represent a potential limitation to its clinical applicability. To this end, additional in vivo investigation is warranted to confirm that ET A antagonism-mediated podocyte protection is due to VEGF. The unprecedented role of VEGF in mediating the protective effect of ET A antagonism on hypoxic podocytes proposed by Harvey et al. makes it possible to envision the ET A receptor/VEGF pathway involvement in other renal diseases characterized by oxidative stress and fibrosis, such as diabetes. Notably, in experimental diabetic nephropathy, a number of studies documented the synergistic renoprotective effect exerted by the association of ET A receptor antagonism with angiotensin-converting enzyme inhibitors (ACEi) [11, 12] . Such positive preclinical results provided the rationale for current trials in patients. Thus, the investigation of whether the effects of combined ACEi -ET A receptor antagonism treatment are related to VEGF production in patients in ongoing trials could be an intriguing way forward.
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